# lung adenocarcinoma (LUAD) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 97193
- Completion tokens: 69687
- Reasoning tokens: 13963
- Total tokens: 166880
- API requests reported: 8
- Elapsed seconds: 184.791
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 957.651
- Question handoff seconds: 970.897
- Final benchmark system: E2seq; file rank 3/5; original repeat 5; model vendor: MiniMax

---
<think>The user is asking for a comprehensive interpretation of prognostic transcriptomic data for lung adenocarcinoma (LUAD) overall survival (OS). Let me carefully analyze the input.

**Data Quality Assessment (Critical First Step):**

Looking at the input table, I notice several red flags:

1. **Extreme HR values**: Many genes have HRs like 5.18e+21, which are astronomically high and biologically implausible. A hazard ratio of 5×10^21 is not a meaningful survival statistic.

2. **P values = 0 and FDR = 0**: These indicate complete separation in the survival data - meaning the Cox model fit was degenerate, likely due to:
   - Very few or zero events in one group
   - All cases in one group censored before any events in the other
   - Quasi-separation or complete separation
   - Very rare events with extreme expression categories

3. **Y_RNA with 163 duplicate rows** showing direction conflict - suggests data preprocessing artifacts

4. **Mixture of lncRNAs, pseudogenes, miRNAs, and protein-coding genes**: The gene list is dominated by:
   - Y-chromosome genes (RBMY1F, FAM9A, USP9YP3, CDY10P, etc.) - relevant given sex differences in LUAD
   - Pseudogenes (RAP1BP2, RBMXP1, ATP5PBP2, etc.)
   - lncRNAs (LINC00448, LINC01312, etc.)
   - miRNAs (MIR509-1, MIR3924, etc.)
   - Some protein-coding genes (DKK1, PITX3, TLE1, FUT4, KRT6A, RGS20, RHOF)

5. **Direction counts**: 96 risk-associated vs 4 protective-associated - heavily skewed

6. **TCP10L3 has HR = 1.93e-22** (protective, P=0) - again biologically implausible

**External Statistical Validation**: NOT available - "External summary: direction concordant=0/0; FDR<=0.05=0"

**Pathway enrichment**: The pre-computed GO/KEGG annotations show:
- Regulation of Wnt signaling pathway (GO:0030111)
- Planar cell polarity pathway (GO:2000096)
- Cell junction disassembly (GO:0150146)
- Wnt signaling pathway
- Glycosphingolipid biosynthesis
- Mannose type O-glycan biosynthesis

These pathway hints seem largely driven by DKK1 (Wnt antagonist) but may not reflect a coherent multi-gene program since most selected genes are lncRNAs/pseudogenes.

**Key protein-coding genes to focus on (with HRs in plausible range):**
- PITX3 (HR=1.43, FDR=3.49e-11)
- DKK1 (HR=1.48, FDR=3.55e-07) - Wnt inhibitor
- TLE1 (HR=1.48, FDR=2.46e-05) - Wnt/Notch co-repressor
- VAX1 (HR=1.33, FDR=9.25e-06) - developmental TF
- LDLRAD3 (HR=1.42, FDR=2.23e-04)
- KRT6A (HR=1.39, FDR=2.78e-04) - keratin
- FUT4 (HR=1.40, FDR=2.93e-04) - fucosyltransferase
- RHOF (HR=1.40, FDR=4.00e-04) - Rho GTPase
- RGS20 (HR=1.35, FDR=5.79e-04) - G protein signaling regulator
- CREG2 (HR=1.33, FDR=1.63e-04)
- RHCG (HR=1.29, FDR=4.73e-04)
- RBMXP1 (HR=0.21, FDR=1.60e-17) - protective, but pseudogene

**Biologically interpretable themes I can defensibly propose:**

1. **Wnt signaling modulation (risk program)**: DKK1 and TLE1 directly suggest altered Wnt pathway activity. DKK1 is a secreted Wnt antagonist, TLE1 is a Groucho/TLE family co-repressor that antagonizes Wnt/β-catenin and Notch signaling. However, this is based on only 2 protein-coding genes.

2. **Y-chromosome / sex chromosome transcripts**: Many of the extreme HRs are from Y-chromosome genes. These should be interpreted as potential confounders related to sex differences in LUAD (males have higher LUAD incidence and often worse outcomes) rather than as biologically meaningful prognostic factors per se.

3. **Epithelial/squamous differentiation (KRT6A, FUT4)**: KRT6A is a keratin associated with squamous differentiation; FUT4 (fucosyltransferase 4) is involved in selectin ligand synthesis. These may relate to histologic subtype or differentiation state.

4. **Small GTPase signaling (RHOF, RGS20)**: RHOF is a Rho family GTPase involved in actin dynamics; RGS20 is a regulator of G-protein signaling. These could reflect cytoskeletal/cell migration programs.

5. **Pseudogene/lncRNA dominance**: The list is dominated by non-coding elements, many of which have no established biological function. These are likely technical artifacts of the Cox model rather than biologically meaningful signals.

**Limitations to emphasize:**
- Extreme HRs (1e+21) indicate numerical instability / quasi-separation
- P=0 FDR=0 are not valid P values - they indicate convergence failures
- Y-chromosome genes likely reflect male sex (a known prognostic factor in LUAD)
- The pathway "enrichment" is driven by a handful of genes (DKK1, TLE1) and does not represent a coherent multi-gene program
- No external cohort validation
- Many of the genes are pseudogenes or uncharacterized lncRNAs with no functional annotation

Now let me structure a complete response that:
1. Issues the data quality warning up front
2. Provides biological interpretation grounded in what's defensible
3. Identifies programs that are supported
4. Names key genes with explicit evidence classes
5. Proposes validation priorities
6. Lists limitations

I should NOT enumerate all 100 genes. I should focus on the biologically interpretable protein-coding genes and the most plausible themes.

Let me also check the literature evidence:
- ITGB1-DT/ARNTL2 axis in LUAD (PMID 34906142)
- ITGB1-DT biomarker in breast cancer (PMID 37690573)
- RhoF worse OS in AML (PMID 34405015)
- KRT6A biomarker for alopecia areata (PMID 42216026)
- Ferritinophagy-related genes in NSCLC (PMID 40124684)
- miRNAs in pancreatic cancer (PMID 36983764)

These provide some context but are mostly off-topic relative to LUAD specifically.

Let me now draft the response.</think>

# Multidimensional Interpretation: LUAD Prognostic Transcriptome (OS)

## 1. Overall Biological Interpretation

**Data-quality warning (read first).** The supplied cohort shows classic signatures of *degenerate survival fits*: (i) ~70 rows have hazard ratios of order 10²¹ or 10⁻²² with P = FDR = 0, (ii) one transcript (Y_RNA) appears 163 times with direction conflict, (iii) Y-chromosome–encoded loci dominate the "risk" side, and (iv) the 4 "protective" genes have protective HRs only when a Y_RNA-style artifact can flip a coefficient. None of these values represent a meaningful per-event hazard estimate; they indicate quasi/complete separation in the Cox likelihood. The four protein-coding genes with numerically plausible HRs (1.2–1.5), PITX3, DKK1, TLE1, and to a lesser extent VAX1, KRT6A, FUT4, RHOF, RGS20, LDLRAD3, CREG2, and RHCG, are the only rows in which the effect size itself can be interpreted biologically. Everything else should be treated as a non-replicated feature with an unstable fit.

Within that defensible subset, the prognostic biology that emerges is consistent with three recurrent axes in aggressive LUAD:

1. **Wnt/β-catenin pathway antagonism**, marked by co-direction of DKK1 (a secreted Wnt inhibitor) and TLE1 (a Groucho/TLE co-repressor of β-catenin and Notch targets), with VAX1 (a developmental transcription factor known to intersect non-canonical Wnt/PCP) also running in the same risk direction.
2. **Epithelial / squamous-like differentiation state**, supported by KRT6A, a keratin typically up-regulated in squamous programs but also seen in LUAD with squamoid features, together with FUT4, an α1,3-fucosyltransferase that generates selectin ligands (sialyl-Lewis antigens) relevant to adhesion/invasion.
3. **Small-GTPase and G-protein signaling rewiring**, supported by RHOF (Rho-family GTPase, actin/cytoskeleton) and RGS20 (RGS protein accelerating Gαi/Gαz GTP hydrolysis).

The vast majority of the remaining "risk" hits are Y-chromosome loci (RBMY1F, FAM9A, USP9YP3, CDY10P, TTTY4C, TEX13A, RBMY2AP, VENTXP7), autosomal pseudogenes (ATP5PBP2, RAP1BP2, MTND1P1, RBMXP1, RNY1P3, DRAXINP1, ETFRF1P1, HMGN2P39, H2AZP7, DIMT1P1, DNM1P49, ATG4AP1, AMMECR1LP1), poorly characterized lncRNAs (LINC00448, LINC01312, LINC01910, LINC02178, LINC02323, LINC02802, LINC00707, ITGB1-DT, CRNDE, FAS-AS1), and "UNMAPPED_ENSEMBL_*" contigs. With FDR ≤ 0.01 in 100/100 rows but P values and HRs clearly non-identifiable, no coherent multi-gene program can be claimed beyond the protein-coding subset. **External statistical validation was not performed** (independent-cohort statistic = not_available, direction-concordant = 0/0); pathway, interaction, and literature records below are contextual only.

---

## 2. Core Biological Programs

I restrict the program list to what the **defensible protein-coding subset** can actually support, and explicitly label each program by its evidence strength.

### Program A — Wnt / β-catenin and Notch signaling attenuation (risk-associated)
- **Direction**: HR > 1 for DKK1, TLE1, VAX1; all risk-associated.
- **Supporting genes**: DKK1 (HR 1.48, FDR 3.5×10⁻⁷), TLE1 (HR 1.48, FDR 2.5×10⁻⁵), VAX1 (HR 1.33, FDR 9.2×10⁻⁶).
- **Best-fit pathway**: Reactome "Signaling by WNT" and GO:0030111 "regulation of Wnt signaling pathway"; TLE1 also maps to Notch co-repression. The retrieved GO/KEGG hint (Regulation of Wnt signaling pathway, Planar Cell Polarity Pathway GO:2000096) is consistent.
- **Why these genes collectively fit**: DKK1 is an extracellular Wnt antagonist whose overexpression in LUAD has been tied to immune-cold microenvironments and worse OS; TLE1 binds TCF/LEF to repress β-catenin targets and also dampens Notch signaling; VAX1 participates in non-canonical Wnt/PCP and anterior neural plate patterning. Co-direction of three Wnt/PCP-axis modulators is the strongest internal coherence in the cohort.
- **Evidence strength**: Supported hypothesis. Three protein-coding genes agree in direction, and the GO/KEGG enrichment hint is driven by them; however, the HRs are moderate (1.3–1.5), not separated, and no independent cohort statistic is supplied.
- **Major limitations**: Small gene count (n = 3); VAX1's role in LUAD specifically is under-documented; no direct physical interaction among DKK1/TLE1/VAX1 is established (they are pathway co-members only).

### Program B — Squamoid / epithelial differentiation with glycan remodeling (risk-associated)
- **Direction**: KRT6A and FUT4 both risk-associated; RHCG and LDLRAD3 co-directionally risk-associated, consistent with altered membrane transport/glyco-programs.
- **Supporting genes**: KRT6A (HR 1.39, FDR 2.8×10⁻⁴), FUT4 (HR 1.40, FDR 2.9×10⁻⁴), RHCG (HR 1.29, FDR 4.7×10⁻⁴), LDLRAD3 (HR 1.42, FDR 2.2×10⁻⁴).
- **Best-fit pathway**: KEGG "Mannose type O-glycan biosynthesis" and "Glycosphingolipid biosynthesis" (FUT4 contributes), plus GO:0008544 "epidermis development" (KRT6A).
- **Why these genes collectively fit**: KRT6A is a keratin typical of squamous epithelium but increasingly recognized as an adverse prognostic feature in LUAD with squamoid morphology; FUT4 adds α1,3-fucosylation to membrane acceptors, generating Lewis antigens used in selectin-mediated adhesion; RHCG is an ammonia transporter also implicated in tumor pH/immune-microenvironment biology; LDLRAD3 is a poorly characterized LDLR-family member recurrent in GWAS.
- **Evidence strength**: Supported hypothesis for the differentiation/glycan axis (two agreeing genes); exploratory for RHCG/LDLRAD3.
- **Major limitations**: Pathway co-membership does not equal physical interaction; no FUT4–KRT6A binding data; "differentiation" is an association, not a causal mechanism.

### Program C — Rho / G-protein signaling and cytoskeletal dynamics (risk-associated)
- **Direction**: RHOF and RGS20 both risk-associated; RHOF has a literature link to worse OS in AML.
- **Supporting genes**: RHOF (HR 1.40, FDR 4.0×10⁻⁴), RGS20 (HR 1.35, FDR 5.8×10⁻⁴).
- **Best-fit pathway**: GO:0007264 "small GTPase mediated signal transduction" (RHOF), R-HSA-418594 "G alpha (i) signalling events" (RGS20). STRING shows RGS20 binding GNAZ (0.95), GNB5 (0.95), GNAI2 (0.82), GNAQ (0.80) and SUCLG2 (0.85); these are direct physical/functional interactions.
- **Why these genes collectively fit**: RHOF remodels actin and is implicated in amoeboid-type migration; RGS20 accelerates GTP hydrolysis on Gαi/Gαz, sharpening heterotrimeric G-protein signaling kinetics. Both are linked to cell migration and cytoskeletal programs that are recurrently activated in aggressive LUAD.
- **Evidence strength**: Supported hypothesis (gene-level), with one literature link (RhoF and worse OS in AML, PMID 34405015) but no LUAD-specific replication.
- **Major limitations**: Only two genes; RHOF and RGS20 do not physically interact (pathway co-membership at most); AML literature is not transferable to LUAD without independent verification.

### Program D — Developmental / lineage transcription factor signature (risk-associated)
- **Direction**: PITX3, VAX1, TLE1 (also in Program A), VAX1 already counted.
- **Supporting genes**: PITX3 (HR 1.43, FDR 3.5×10⁻¹¹ — the lowest P among the defensible set), plus VAX1/TLE1.
- **Best-fit pathway**: GO:0007399 "nervous system development" (developmental TF family), with overlap into Program A.
- **Why these genes collectively fit**: All three encode homeodomain/paired-like developmental TFs that are normally silenced in adult lung; their ectopic expression in LUAD suggests an embryonic-like lineage state.
- **Evidence strength**: Exploratory hypothesis. Strongest P value in the defensible subset (PITX3), but the functional link to LUAD progression is not established by external replication.
- **Major limitations**: No LUAD mechanism literature for PITX3; no independent-cohort statistic; overlap with Program A risks double-counting the same gene.

### Program E — Y-chromosome / sex-correlated transcript block (technical / confounder, risk-associated)
- **Direction**: 18+ of the largest "risk" HRs are Y-chromosome loci (RBMY1F, FAM9A, USP9YP3, CDY10P, TTTY4C, TEX13A, RBMY2AP, VENTXP7, RP11-316I3.1-related), plus TCAM-family contigs.
- **Why these cluster**: Male LUAD patients have ~25–40 % worse OS than female patients after stage adjustment; tissue-level detection of Y-linked transcripts in a male-enriched subcohort will absorb the sex effect and produce extreme HRs in a Cox model that is not stratified on sex.
- **Evidence strength**: This is **a confounder interpretation, not a biological program**. Extreme HRs and P=0 are consistent with quasi-separation introduced when one sex is rare in one expression stratum.
- **Major limitations**: Without sex-stratified reanalysis, this block should not be reported as prognostic biology. Sex of the cohort and sex-stratified CIs are needed.

---

## 3. Key Genes and Interaction Modules

I list the ten most defensible candidates, restricted to the numerically interpretable subset. Each entry is annotated by evidence type (direct input / interaction / pathway / literature / tissue).

1. **DKK1** — risk-associated, HR 1.48, FDR 3.5×10⁻⁷. *Program A*. Direct input statistic; pathway co-membership with Wnt/β-catenin; literature supports DKK1 as an immune-evasion / Wnt-antagonist factor in NSCLC but does not directly replicate this HR. No direct physical interaction with other selected genes.
2. **TLE1** — risk-associated, HR 1.48, FDR 2.5×10⁻⁵. *Program A + D*. Direct input statistic; GO:0003712 "transcription co-repressor activity"; TLE1 is a known β-catenin/TCF and Notch co-repressor. Pathway co-membership with DKK1 only.
3. **VAX1** — risk-associated, HR 1.33, FDR 9.2×10⁻⁶. *Program A + D*. Direct input statistic; STRING reports an interaction with ASXL2 (a chromatin regulator) — this is a *physical interaction from external data*, not within the selected gene set. Pathway co-membership with non-canonical Wnt/PCP (GO:2000096).
4. **PITX3** — risk-associated, HR 1.43, FDR 3.5×10⁻¹¹ (strongest P in the defensible set). *Program D*. Direct input statistic; no LUAD-specific literature in the supplied pack. No interaction within the selected set.
5. **KRT6A** — risk-associated, HR 1.39, FDR 2.8×10⁻⁴. *Program B*. Direct input statistic; GO:0008544 epidermis development; literature supports KRT6A as a biomarker in alopecia areata (PMID 42216026), not LUAD.
6. **FUT4** — risk-associated, HR 1.40, FDR 2.9×10⁻⁴. *Program B*. Direct input statistic; STRING shows direct physical interactions with **B3GNT3** and **B4GALT1** (glycosylation enzymes) at confidence ≥ 0.9 — these are *direct physical interactions* in external data, but neither partner is in the selected set, so they are not gene-gene interactions within the prognostic signature.
7. **RHOF** — risk-associated, HR 1.40, FDR 4.0×10⁻⁴. *Program C*. Direct input statistic; STRING shows direct physical interaction with **ACTN1** (α-actinin) and **ARHGAP1** (Rho GAP) — direct physical interactions external to the cohort. Literature (PMID 34405015) links RhoF to worse OS in AML; this is an independent disease, so the literature is supportive of the gene's role in migration but not directly replicated in LUAD.
8. **RGS20** — risk-associated, HR 1.35, FDR 5.8×10⁻⁴. *Program C*. Direct input statistic; STRING shows direct physical interactions with **GNAZ** (0.95), **GNB5** (0.95), **GNAI2** (0.82), **GNAQ** (0.80), and **SUCLG2** (0.85) — direct physical interactions, all external to the selected gene set. GTEx shows brain-restricted expression (cortex/caudate 13–24 TPM), with very low expression in normal lung (0.10–0.24 TPM), meaning RGS20 overexpression in LUAD is a striking deviation worth validating.
9. **LDLRAD3** — risk-associated, HR 1.42, FDR 2.2×10⁻⁴. STRING shows direct physical interaction with **APP** (amyloid precursor protein) — direct physical interaction external to the cohort; GO:protein binding; recurrent in GWAS but no LUAD mechanism. Exploratory biomarker candidate.
10. **CREG2** — risk-associated, HR 1.33, FDR 1.6×10⁻⁴. *Program B (membrane/glyco adjacent)*. Direct input statistic; no strong external LUAD link. Worth keeping as a candidate pending replication.

**Interaction caveats applied.** Within the 100 selected genes, no direct physical pair is documented in the supplied evidence; every physical interaction listed above is to an external partner (ACTN1, ARHGAP1, B3GNT3, B4GALT1, GNAZ, GNB5, GNAI2, GNAQ, SUCLG2, ASXL2, APP). Therefore, no within-signature direct physical interaction can be claimed at this time.

**Protective candidates (use with caution).** Only RBMXP1 (HR 0.21), CMAHP (HR 0.71), CRNDE (HR 0.72), and TCP10L3 (HR 1.93×10⁻²²) have HR < 1. RBMXP1 is an RBMY pseudogene; its protective signal is partly confounded with female sex (RBMY-family loci are male-restricted). CRNDE has prior oncogene literature in colorectal/glioblastoma, so its protective direction in LUAD would need independent confirmation.

---

## 4. Validation Priorities

### V1. **Stratified Cox replication of the protein-coding subset** — *Confounding / composition check* + *Biomarker*
- **Why prioritized**: Until the four numerically stable protein-coding genes (DKK1, TLE1, VAX1, PITX3) are re-fit in a sex-stratified, event-counted model, the cohort statistic cannot be cited as replication. This is the single highest-yield step.
- **Current dataset evidence**: Defensible HRs in 1.3–1.5 range with FDR < 10⁻⁴.
- **External evidence**: DKK1 and Wnt-antagonism literature in NSCLC; PITX3, VAX1, TLE1 each have limited LUAD literature.
- **Next step**: Pull TCGA-LUAD (and at least one independent cohort such as MSK-IMPACT LUAD or a CPTAC cohort), recompute univariable Cox HRs for DKK1/TLE1/VAX1/PITX3, and confirm direction and significance after adjusting for sex, stage, smoking, and tumor purity.
- **Status**: **Exploratory hypothesis** until the replication is done.

### V2. **Sex-stratified reanalysis of the Y-chromosome / RBMY / FAM9A cluster** — *Confounding / composition check*
- **Why prioritized**: This cluster dominates the "extreme-HR" rows and is a known surrogate for male sex; without stratification, it cannot be reported as a prognostic biology.
- **Current dataset evidence**: 18+ rows with HR ~ 10²¹, P = 0.
- **External evidence**: Documented male-vs-female OS gap in LUAD; GWAS/sex-difference studies (PMID 35022708 in the supplied literature block is on inguinal hernia, illustrative of sex-stratified methodology only).
- **Next step**: Run a sex-stratified Cox; if the Y-cluster HR collapses, the "risk" signal is a confounder, not biology.
- **Status**: **Exploratory / likely artifactual**.

### V3. **DKK1 and TLE1 mechanism in LUAD Wnt-antagonism** — *Mechanistic hypothesis*
- **Why prioritized**: The strongest coherent internal program (three agreeing genes, plausible GO/KEGG mapping).
- **Current dataset evidence**: DKK1 (HR 1.48), TLE1 (HR 1.48), with VAX1 (HR 1.33) supporting non-canonical Wnt.
- **External evidence**: DKK1 linked to immune exclusion and worse OS in multiple cancers; TLE1's role as β-catenin/Notch co-repressor is well established biochemically.
- **Next step**: IHC for DKK1 and TLE1 on a LUAD TMA, correlate with β-catenin localization (membrane vs nuclear), and test whether DKK1-high tumors are Wnt-low (consistent with extracellular antagonism) versus Wnt-high (consistent with feedback compensation).
- **Status**: **Supported hypothesis**, not yet established for LUAD.

### V4. **KRT6A / FUT4 as a squamoid-differentiation biomarker** — *Biomarker*
- **Why prioritized**: Two agreeing protein-coding genes with moderate HR; KRT6A and FUT4 are measurable by IHC / lectin staining and could be deployed in routine pathology.
- **Current dataset evidence**: KRT6A HR 1.39, FUT4 HR 1.40, both FDR ~ 3×10⁻⁴.
- **External evidence**: KRT6A is a standard keratin; FUT4 is biochemically characterized (B3GNT3/B4GALT1 partners). No LUAD-specific replication in the supplied pack.
- **Next step**: Validate on a TMA with outcome annotation, adjusting for histologic subtype (lepidic/acinar/papillary/micropapillary/solid).
- **Status**: **Exploratory hypothesis**.

### V5. **RHOF and RGS20 cytoskeletal / G-protein axis as a migration / therapy-resistance module** — *Therapeutic target* + *Interaction / network hypothesis*
- **Why prioritized**: Both genes are mechanistically actionable (RHOF as a Rho GTPase, RGS20 as a Gαi/z modulator) and have direct physical interaction partners in STRING, but no LUAD-specific replication.
- **Current dataset evidence**: HR 1.40 and 1.35, FDR ~ 4–6×10⁻⁴.
- **External evidence**: RHOF linked to worse OS in AML (PMID 34405015); RGS20 interacts with GNAZ/GNB5 at high STRING confidence.
- **Next step**: Test whether RHOF or RGS20 knockdown reduces LUAD cell migration/invasion in 2D/3D; probe whether RGS20 alters Gαi signaling output in LUAD lines.
- **Status**: **Exploratory hypothesis**. Drug-target existence is not, by itself, evidence of therapeutic value.

---

## 5. Evidence Grounding (per category)

- **Direct evidence from the input dataset**: Only for the rows with numerically plausible HRs (DKK1, PITX3, TLE1, VAX1, KRT6A, FUT4, RHOF, RGS20, LDLRAD3, CREG2, RHCG, plus the four protective rows with caveats). All rows with HR ≥ 10⁹ or HR ≤ 10⁻⁹ should be treated as **insufficient direct evidence** because the Cox fit did not converge to a meaningful maximum-likelihood estimate.
- **Pathway / ontology evidence**: Recurrence of "Regulation of Wnt signaling pathway" (GO:0030111) and "Planar Cell Polarity Pathway" (GO:2000096) in the retrieved Reactome/GO batch is driven primarily by DKK1, TLE1, and VAX1 — i.e., the signal is internally consistent with Program A but not independent of it.
- **Protein / regulatory network evidence**: STRING/IntAct supplied physical interactions for RGS20, RHOF, FUT4, FAM9A, LDLRAD3, and VAX1; none of the interactors are within the 100-gene prognostic signature. Therefore these are *external-to-cohort* interaction records and do not by themselves validate the prognostic claim.
- **Disease-association evidence**: cBioPortal returned 51/100, ClinVar 30/100, OpenTargets 55/100, GWAS 100/100 — high coverage but these are *cohort-agnostic* association records and do not constitute replication.
- **Tissue / expression evidence**: GTEx shows brain-enriched expression for RGS20 and low lung expression — a potential anchor for the prognostic deviation. This is tissue-context evidence, not a survival statistic.
- **Drug / therapeutic evidence**: ChEMBL 16/100 and ClinicalTrials 6/100 — these do **not** establish efficacy of any compound in LUAD.
- **Published literature evidence**: PMID 34906142 (ITGB1-DT/ARNTL2 in LUAD), PMID 37690573 (ITGB1-DT in breast cancer), PMID 40124684 (ferritinophagy in NSCLC), PMID 34405015 (RhoF in AML), PMID 42216026 (KRT6A in alopecia areata), PMID 36983764 (miRNAs in pancreatic cancer), PMID 35022708 (sex-stratified GWAS methodology). These are supportive contextual citations only; none directly replicates the supplied HRs in an independent LUAD OS cohort.

**Independence check**: Pathway (Reactome/QuickGO) and STRING records often share underlying curated databases and literature, so they should be treated as a partially redundant source bundle, not as two independent confirmations.

**Conflict**: DKK1 and TLE1 (Program A) point to *inhibition* of canonical Wnt signaling, but elevated DKK1 has been reported in NSCLC with *intact* β-catenin pathway activity in some series. This conflict can be addressed by measuring β-catenin localization alongside DKK1/TLE1 IHC.

---

## 6. Limitations and Alternative Explanations

1. **Numerical degeneracy of the Cox fits (HR ≈ 10²¹, P = FDR = 0).** The dominant pattern in this table is not a real hazard estimate but a quasi/complete separation failure. Re-fitting with penalized Cox regression (elastic-net / ridge), removing zero-variance strata, and verifying event counts per expression quartile are the minimal remediation. **No biological conclusion should be drawn from any row with HR > 10⁶ or HR < 10⁻⁶.**
2. **Sex / Y-chromosome confounding.** The RBMY/FAM9A/USP9YP3/CDY10P/TTTY4C block is almost certainly a male-sex surrogate. Sex-stratified reanalysis is essential. Female-enriched LUAD cohorts may show "protective" HRs for the same Y loci purely because of female enrichment.
3. **Tumor purity and stromal / immune contamination.** DKK1 in particular is expressed by stromal fibroblasts and immune cells; tumor-purity-adjusted estimates (ESTIMATE, AbsCN-seq, or pathologist-reviewed tumor cellularity) are required before assigning a tumor-cell-autonomous role.
4. **Tissue-composition differences (differentiation state).** KRT6A and FUT4 may mark a squamous-like transcriptional subtype of LUAD; if the cohort over-samples such tumors, the HRs will be confounded with histology. Adjustment for histologic subtype is required.
5. **Batch / platform and small-subgroup effects.** Extreme HRs are characteristic of small-sample-size effects (sparse events in a high-expression quartile). Cohort size, events-per-variable, and platform (RNA-seq vs microarray) should be reported before treating any HR as stable.

Together, these five factors plausibly account for the bulk of the cohort's signal; only after they are explicitly addressed can the Programs A–D be elevated above "supported hypothesis" status.

---

## Bottom line

The defensible, biologically interpretable fraction of this LUAD prognostic signature is small and centered on **Wnt-antagonism (DKK1, TLE1, VAX1), squamoid differentiation (KRT6A, FUT4), and cytoskeletal/G-protein signaling (RHOF, RGS20)**, with **PITX3** as the strongest single P value. The 90+ remaining rows — dominated by Y-linked loci, pseudogenes, and uncharacterized lncRNAs with degenerate Cox fits — should not be cited as prognostic biology until the model is re-fit with sex stratification, penalized regression, and at least one independent cohort statistic. **External statistical validation was not performed in this analysis.**

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=76, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 53/100 selected items (records returned); cbioportal 51/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 6/100 selected items (records returned); clinvar 30/100 selected items (records returned); ensembl 11/100 selected items (partially returned; some queries failed); europepmc 362 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 56/100 selected items (partially returned; some queries failed); intact 18/100 selected items (records returned); mygene 59/100 selected items (records returned); omnipath 3/100 selected items (records returned); opentargets 55/100 selected items (records returned); pubmed 202 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 17/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 17/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 2/100 selected items (records returned); string 14/100 selected items (records returned); trrust 4/100 selected items (records returned)
